A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
The group could soon provide clarity on CTX112’s regulatory path.
The THIO-104 study listing is live, along with questions about funding the trial.
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
Golcadomide will begin a new pivotal trial in follicular lymphoma.
The company will soon start a pivotal trial of its IL-12 gene therapy, but cash is short.
